AbbVie (ABBV) Declares $0.96 Quarterly Dividend; 3.9% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
AbbVie (ABBV) Highlights Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab
June 15, 2018 5:42 AM EDTAbbVie (NYSE: ABBV) today announced the presentation of investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the pivotal Phase 3 MURANO trial of venetoclax, a first-in-class oral B-cell lymphoma-2 (BCL-2) inhibitor, in combination with rituximab (VenR) in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). Of the 121 patients who achieved uMRD (meaning less than one CLL cell in 10,000 white blood cells were detectable using a standardized test2) at the end of combination therapy (EOCT), 83 percent (n=100) maintained uMRD and were progression-free for a median of 13.8 months (range,... More
Incyte (INCY) Strength Tied to AbbVie's (ABBV) M&A Comment - Bloomberg
June 14, 2018 12:39 PM EDTIncyte (NASDAQ: INCY) strength recently was tied to AbbVie's (NYSE: ABBV) M&A commentary on Tuesday, according to Bloomberg, citing Jefferies health-care trading strategist Jared Holz. The strong tape and anticipation of Incyte's R&D day... More
AbbVie (ABBV) Highlights Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at EULAR 2018
June 13, 2018 5:49 AM EDTAbbVie (NYSE: ABBV) today presented new patient-reported outcome data during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam from three Phase 3 trials evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe rheumatoid arthritis.1,2,3 Improvements in pain, physical function and morning joint stiffness were reported after 12 weeks of treatment with upadacitinib (15 mg and 30 mg, once-daily) in SELECT-NEXT and SELECT-BEYOND and after 14 weeks of treatment in SELECT-MONOTHERAPY.1,2,3 Additionally, improvements were reported in fatigue and work instability in SELECT-NEXT and patients'... More
